Why CSF3R‑mutant AML cells fail to mature into normal white blood cells
Mechanisms of differentiation blockade in CSF3R-mutant AML
Researchers are learning how CSF3R and related gene changes stop leukemia cells from maturing in people with CSF3R‑mutant acute myeloid leukemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11378903 on NIH RePORTER |
What this research studies
From a patient's point of view, the team is studying leukemia samples and lab models that carry CSF3R mutations together with changes in CEBPA or core binding factor (CBF) genes to see why the cancer cells stay immature. They will look at how these genetic changes alter signaling pathways (including STAT proteins) and the epigenetic control of myeloid cell development. The work combines analyses of human-derived samples with molecular and cellular experiments in the lab to map the mechanisms of differentiation arrest. Findings are intended to point toward targets that could be used to restore normal maturation of blood cells in this AML subtype.
Who could benefit from this research
Good fit: Ideal candidates are people diagnosed with acute myeloid leukemia whose leukemia carries CSF3R mutations, especially those with co‑occurring CEBPA mutations or CBF translocations.
Not a fit: Patients without CSF3R mutations (or with entirely different leukemia subtypes) are unlikely to benefit directly from this specific research.
Why it matters
Potential benefit: If successful, this work could point to new ways to make CSF3R‑mutant leukemia cells mature and potentially improve outcomes for patients with this subtype of AML.
How similar studies have performed: Differentiation therapy has been highly successful in a related AML subtype (APL), but targeting CSF3R‑driven AML is a newer, less‑tested approach.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Maxson, Julia E — Oregon Health & Science University
- Study coordinator: Maxson, Julia E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.